Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.